



## Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

January 22, 2026

- Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET
- Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026

WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- [Arcutis Biotherapeutics, Inc.](#) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.

A live webcast of the call and related presentation materials will be available on the "[Events](#)" section of the Company's website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.

Arcutis also announced it will participate in the following investor conference:

**Guggenheim Emerging Outlook: Biotech Summit**  
**Fireside Chat:** Wednesday, February 11, 2026 at 11:30 a.m. ET

The webcast for this conference may be accessed via the "[Events](#)" section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.

### About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis' unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit [www.arcutis.com](http://www.arcutis.com) or follow Arcutis on [LinkedIn](#), [Facebook](#), [Instagram](#), and [X](#).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company's current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the "Risk Factors" section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

### Contacts:

#### **Media**

Amanda Sheldon, Head of Corporate Communications  
[media@arcutis.com](mailto:media@arcutis.com)

#### **Investors**

Brian Schoelkopf, Head of Investor Relations  
[ir@arcutis.com](mailto:ir@arcutis.com)